Abstract
Increasing evidence suggests that μ opioid receptor (MOP) expression is altered during the development of and withdrawal from substance dependence. Although anti-MOP antibodies have been hypothesized to be useful for estimating MOP expression levels, inconsistent MOP molecular weights (MWs) have been reported in studies using anti-MOP antibodies. In the present study, we generated a new anti-MOP antibody (N38) against the 1-38 amino acid sequence of the mouse MOP N-terminus and conducted Western blot analysis with wildtype and MOP knockout brain lysates to determine the MWs of intrinsic MOP. The N38 antibody detected migrating bands with relative MWs of 60-67 kDa in the plasma membrane fraction isolated from wildtype brain, but not from the MOP knockout brain. These migrating bands exhibited semi-linear density in the range of 3-30 μg membrane proteins/lane. The N38 antibody may be useful for quantitatively detecting MOP.
Keywords: Knockout mice, μ opioid receptor, quantification, Western blot analysis, alcohol-dependent, chronic cocaine, downregulates MOP mRNA, immunohistochemistry, MOP binding, mRNA levels, MOP proteins
Current Neuropharmacology
Title: Quantitative Detection of μ Opioid Receptor: Western Blot Analyses Using µ Opioid Receptor Knockout Mice
Volume: 9 Issue: 1
Author(s): Shinya Kasai, Hideko Yamamoto, Etsuko Kamegaya, George R. Uhl, Ichiro Sora, Masahiko Watanabe and Kazutaka Ikeda
Affiliation:
Keywords: Knockout mice, μ opioid receptor, quantification, Western blot analysis, alcohol-dependent, chronic cocaine, downregulates MOP mRNA, immunohistochemistry, MOP binding, mRNA levels, MOP proteins
Abstract: Increasing evidence suggests that μ opioid receptor (MOP) expression is altered during the development of and withdrawal from substance dependence. Although anti-MOP antibodies have been hypothesized to be useful for estimating MOP expression levels, inconsistent MOP molecular weights (MWs) have been reported in studies using anti-MOP antibodies. In the present study, we generated a new anti-MOP antibody (N38) against the 1-38 amino acid sequence of the mouse MOP N-terminus and conducted Western blot analysis with wildtype and MOP knockout brain lysates to determine the MWs of intrinsic MOP. The N38 antibody detected migrating bands with relative MWs of 60-67 kDa in the plasma membrane fraction isolated from wildtype brain, but not from the MOP knockout brain. These migrating bands exhibited semi-linear density in the range of 3-30 μg membrane proteins/lane. The N38 antibody may be useful for quantitatively detecting MOP.
Export Options
About this article
Cite this article as:
Kasai Shinya, Yamamoto Hideko, Kamegaya Etsuko, R. Uhl George, Sora Ichiro, Watanabe Masahiko and Ikeda Kazutaka, Quantitative Detection of μ Opioid Receptor: Western Blot Analyses Using µ Opioid Receptor Knockout Mice, Current Neuropharmacology 2011; 9 (1) . https://dx.doi.org/10.2174/157015911795016921
DOI https://dx.doi.org/10.2174/157015911795016921 |
Print ISSN 1570-159X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6190 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Serotonergic Drugs for Depression and Beyond
Current Drug Targets Targeting of α7 Nicotinic Acetylcholine Receptors in the Treatment of Schizophrenia and the Use of Auditory Sensory Gating as a Translational Biomarker
Current Pharmaceutical Design Role of the Autonomic Nervous System and Neuropeptides in the Development of Obesity in Humans: Targets for Therapy?
Current Pharmaceutical Design Understanding Abnormal c-JNK/p38MAPK Signaling in Amyotrophic Lateral Sclerosis: Potential Drug Targets and Influences on Neurological Disorders
CNS & Neurological Disorders - Drug Targets Ibandronate in Benign Bone Disease
Reviews on Recent Clinical Trials From Nature to Market: Examples of Natural Products that Became Drugs
Recent Patents on Biotechnology Expression and Function of Organic Cation and Anion Transporters (SLC22 Family) in the CNS
Current Pharmaceutical Design Invertebrate Models of Dystonia
Current Neuropharmacology Boronic Acid-based Enzyme Inhibitors: A Review of Recent Progress
Current Medicinal Chemistry Glucocorticoid-Induced Hypertension and Tetrahydrobiopterin (BH4), a Common Cofactor for the Production of Vasoactive Molecules
Current Hypertension Reviews Neurodegenerative Diseases and Flavonoids: Special Reference to Kaempferol
CNS & Neurological Disorders - Drug Targets Processing and Regulation Mechanisms within Antigen Presenting Cells: A Possibility for Therapeutic Modulation
Current Pharmaceutical Design Hypertension and Heart Failure with Preserved Ejection Fraction: Connecting the Dots
Current Vascular Pharmacology Melanocortin Receptor Type 3 as a Potential Target for Anti-Inflammatory Therapy
Current Drug Targets - Inflammation & Allergy Potential Applications of Hydrogen Sulfide-Induced Suspended Animation
Current Medicinal Chemistry The Latent Structure of Mental Disorders: A Taxometric Update on the Categorical vs Dimensional Debate
Current Psychiatry Reviews MPP+ Analogs Acting on Mitochondria and Inducing Neuro-Degeneration
Current Medicinal Chemistry In Silico Validation and Structure Activity Relationship Study of a Series of Pyridine-3-carbohydrazide Derivatives as Potential Anticonvulsants in Generalized and Partial Seizures
Central Nervous System Agents in Medicinal Chemistry MicroRNAs and the Warburg Effect: New Players in an Old Arena
Current Gene Therapy The Palmitoylethanolamide Family: A New Class of Anti-Inflammatory Agents ?
Current Medicinal Chemistry